EX-10.35





 Exhibit 10.35 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HORIZON THERAPEUTICS PLC HAS
DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO HORIZON THERAPEUTICS PLC IF PUBLICLY DISCLOSED. 

AMENDED AND RESTATED 

LICENSE AGREEMENT 

BETWEEN 
 HORIZON ORPHAN
LLC 
 AND 
 THE
REGENTS OF THE UNIVERSITY OF CALIFORNIA 
 FOR 

CASE NOS. SD2006-092, SD2017-110, SD2017-113 AND SD2017-236 












 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1.
	 	DEFINITIONS	  	 	2	 
			
	 ARTICLE 2.
	 	GRANTS	  	 	4	 
			
	 ARTICLE 3.
	 	CONSIDERATION	  	 	6	 
			
	 ARTICLE 4.
	 	REPORTS, RECORDS AND PAYMENTS	  	 	13	 
			
	 ARTICLE 5.
	 	PATENT MATTERS	  	 	16	 
			
	 ARTICLE 6.
	 	GOVERNMENTAL MATTERS	  	 	20	 
			
	 ARTICLE 7.
	 	TERMINATION OR EXPIRATION OF THE AGREEMENT	  	 	21	 
			
	 ARTICLE 8.
	 	LIMITED WARRANTY AND INDEMNIFICATION	  	 	23	 
			
	 ARTICLE 9.
	 	USE OF NAMES AND TRADEMARKS	  	 	25	 
			
	 ARTICLE 10.
	 	MISCELLANEOUS PROVISIONS	  	 	25	 













 AMENDED AND RESTATED LICENSE AGREEMENT 

This agreement (“Agreement”) is made by and between Horizon Orphan LLC, as successor in interest to Raptor Pharmaceuticals, Inc.
(f/k/a Encode Pharmaceuticals, Inc.), a Delaware limited liability company having an address at 150 South Saunders Road, Lake Forest, Illinois 60045 (“LICENSEE”) and The Regents of the University of California, a California corporation
having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California, San Diego, Office of Innovation and
Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California 92093-0910 (“UCSD”). This Agreement is being entered into as of the date of last signature below (“Execution Date”) and is deemed effective as of
October 31, 2007 (“Effective Date”). 
 RECITALS 

WHEREAS, as of the Execution Date hereof, UNIVERSITY and LICENSEE are parties to that certain License Agreement dated as of
October 30, 2012 (entered into as an Amended and Restated License Agreement), as further amended effective as of March 1, 2013 and as of December 16, 2013 (as amended, the “Prior Agreement”), which agreement grants specific
rights to the inventions disclosed in UCSD Disclosure Docket No. SD SD2006-092 and titled “Enterically Coated Cysteamine”, made in the course of research at UCSD by Drs. Ranjan Dohil and Jerry Schneider; SD2017-110 “Methods of
treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds”, made with Licensee in the course of research at UCSD by Dr. Dohil; SD2017-113 “Formulations of cysteamine and cystamine”, made in the course of research
at UCSD by Dr. Dohil; and SD2017-236 “Delayed release cysteamine bead formulation”, made with Licensee in the course of research at UCSD by Dr. Dohil (hereinafter and collectively, the “Invention” and
“Inventors”) and covered by Patent Rights (as defined herein) and Technology (as defined herein);  
 WHEREAS,
LICENSEE is desirous of obtaining certain rights from UNIVERSITY for commercial development, use, and sale of the Invention, and the UNIVERSITY is willing to grant such rights.  

WHEREAS LICENSEE and UNIVERSITY now wish to restate and further amend the Prior Agreement in order to modify certain terms and
conditions thereof in light of the development and commercialization activities that have occurred and are planned with respect to the Licensed Product(s) (as defined below); and 

WHEREAS, as of the Execution Date hereof, UNIVERSITY and LICENSEE are parties to that certain License Agreement dated as of
December 12, 2012, as amended, with regard to an invention titled “Intravenous cysteamine for rapid elevation of adiponectin levels during myocardial infarction and other situations of oxidative stress/ischemia” (the “CV
License”), and the parties are terminating the CV License Agreement as of the Execution Date, and UNIVERSITY has requested, and LICENSEE is willing to accommodate, certain amendments to the Prior Agreement as a result of such termination, as
set forth herein. 
 NOW, THEREFORE, the parties agree: 

  
 1 













 ARTICLE 1. DEFINITIONS 

The terms, as defined herein, shall have the same meanings in both their singular and plural forms. 

1.1 “Affiliate” means any corporation or other business entity which is bound in writing by LICENSEE to the terms set forth in this
Agreement and in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which LICENSEE is owned or controlled directly or
indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least fifty percent (50%), then an
“Affiliate” includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law. 

1.2 “Commercially Reasonable Efforts” means, as the case may be, exerting such efforts and employing such resources as would normally
and objectively be exerted or employed by [***], taking into account the competitiveness of the relevant marketplace, the patent, intellectual property and development positions of third parties, the applicable regulatory situation, the
pricing/reimbursement situation, the commercial viability of the product and [***]. 
 1.3 “Cystinosis Indication” means the
diagnosis, prevention or treatment of cystinosis, including nephropathic cystinosis. 
 1.4 “Field” means all modes of
administration and uses whatsoever and, beginning on the Execution Date, specifically excluding intravenous administration for treatment of cardiovascular and ischemic injury or disease. 

1.5 “Generic Product” means, with respect to a Licensed Product, any pharmaceutical or biological product that (i) is
distributed by a third party under an application for approval approved by a regulatory authority in reliance, in whole or in part, on the prior approval (or on safety or efficacy data submitted in support of the prior approval) of such Licensed
Product, including any product authorized for sale (a) in the U.S. pursuant to Section 505(b)(2) or Section 505(j) of the Act (21 U.S.C. 355(b)(2) and 21 U.S.C. 355(j), respectively), (b) in the EU pursuant to a provision of
Articles 10, 10a or 10b of Parliament and Council Directive 2001/83/EC as amended (including an application under Article 6.1 of Parliament and Council Regulation (EC) No 726/2004 that relies for its content on any such provision) or (c) in any
other country or jurisdiction pursuant to all equivalents of such provisions or (ii) is otherwise substitutable under applicable law for such Licensed Product when dispensed without the intervention of a physician or other health care provider
with prescribing authority. 
 1.6 “HD Indication” means the diagnosis, prevention or treatment of Huntington’s Disease. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 2 













 1.7 “Licensed Method” means any method that uses Technology, or that is claimed in
Patent Rights (as defined below), the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement, of any pending or issued claim within Patent
Rights. 
 1.8 “Licensed Product” means any service, composition or product that uses Technology, or that is claimed in Patent
Rights, or that is produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or
contributory infringement, of any pending or issued claim within the Patent Rights. 
 1.9 “NASH Indication” means the diagnosis,
prevention or treatment of nonalchoholic steatohepatitis. 
 1.10 “Net Sales” means [***]. 

1.11 “Patent Costs” means [***]. 

1.12 “Patent Rights” means [***]. 

The “Patent Rights” in which UNIVERSITY has rights as of the Execution Date are set forth in Exhibit A, which are all such patent
applications or patents described in this Paragraph 1.12 as of the Execution Date. 
 1.13 “Regulatory Authority” means
(a) the FDA in the United States or (b) any equivalent agency or governmental authority in any country or other jurisdiction outside the United States that has responsibility for granting any licenses or approvals necessary for the
marketing and/or sale of a Licensed Product in such country or other jurisdiction (including, without limitation, any supra-national agency such as the “European Medicines Agency” (EMA)). 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 3 













 1.14 “Royalty Term” means, with respect to each Licensed Product, the period
beginning on the date of the first commercial sale of such Licensed Product and ending on the last to occur of: (i) the expiration of the last-to-expire Patent Rights in the applicable country that covers the making, sale, offer for sale or
import of such Licensed Product in such country; and (ii) the twentieth (20th) anniversary of the first commercial sale of such Licensed Product. 

1.15 “Sublicense” means an agreement with a third party that is not an Affiliate of LICENSEE for the purpose of (i) granting
rights under the Patent Rights to make, have made, use, sell or import Licensed Products; (ii) granting an option under the Patent Rights to make, have made, use, sell or import Licensed Products; or (iii) forbearing the enforcement of any
Patent Rights granted to LICENSEE under this Agreement. “Sublicensee” means a third party that is not an Affiliate which enters into a Sublicense. 

1.16 “Sublicense Fees” means all upfront fees, milestone payments and similar license fees received by LICENSEE from its Sublicensees
in consideration for the grant of a Sublicense, but excluding: 
 (i) any royalty payments; 

(ii) payments for equity or debt securities of LICENSEE (except to the extent such payments exceed the fair market value of such securities
upon date of receipt, in which case such premiums over fair market value shall be deemed to be “Sublicense Fees”); 
 (iii)
research or development funding to be applied directly to the future research and/or development of Licensed Products; and 
 (iv) payments
and reimbursement of Patent Costs paid to UNIVERSITY by LICENSEE with respect to the filing, preparation, prosecution or maintenance of the Patent Rights. 

1.17 “Technology” means the written technical information and know-how relating to the Invention, which the UNIVERSITY provides to
LICENSEE prior to and during the Term of this Agreement. 
 1.18 “Term” means the period of time beginning on the Effective Date
and, unless earlier terminated in accordance herewith, ending on the date of expiration of the last Royalty Term for the last Licensed Product in all countries in the Territory. 

1.19 “Territory” means world-wide. 

ARTICLE 2. GRANTS 
 2.1
License. Subject to the limitations set forth in this Agreement, UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, a license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for
sale, and to import and have imported Licensed Products and to practice Licensed Methods and to use Technology, in the Field within the Territory. The license granted herein is exclusive for Patent Rights and non-exclusive for Technology. Upon
expiration of the Royalty Term and provided that all royalty 

  
 4 













 
payments due hereunder have been paid, LICENSEE shall retain the license granted herein on a continuing fully paid-up royalty-free basis. 

2.2 Sublicense. 
 (a) The
license granted in Paragraph 2.1 includes the right (i) to grant Sublicenses to third parties, through multiple tiers of Sublicensees, during the Term but only for as long the license is exclusive with respect to any Patent Rights and
(ii) to grant sublicenses to Affiliates, through multiple tiers of Affiliates and Sublicensees. 
 (b) With respect to Sublicense
granted pursuant to Paragraph 2.2(a), LICENSEE shall: 
 (i) not receive, or agree to receive, any non-cash consideration in lieu of cash as
consideration from a third party under a Sublicense granted pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY; 

(ii) to the extent applicable to the rights granted under a Sublicense, include all of the rights of and obligations due to UNIVERSITY and
contained in this Agreement; 
 (iii) within [***] of the execution of the Sublicense agreement, provide UNIVERSITY with a copy of each
Sublicense issued; and 
 (iv) collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees
and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees. 
 (c) Upon termination of this Agreement
for any reason, UNIVERSITY may terminate a Sublicensee but will allow any Sublicenses granted by LICENSEE or its Affiliates prior to such termination to survive as direct licenses from UNIVERSITY provided a) that the Sublicensee is in good standing
upon termination of this Agreement with Licensee; and b) the Sublicensee is not currently involved in litigation as an adverse party to the UNIVERSITY. In no case, however, will UNIVERSITY be bound by duties and obligations contained in any
Sublicense that extends beyond the duties and obligations of the UNIVERSITY set forth in this Agreement. If a Sublicense survives, the Sublicensee will promptly agree in writing to be bound by the applicable terms of this Agreement, including but
not limited to, in lieu of the payment obligations under the applicable Sublicense agreement from the LICENSEE to said Sublicensee, payment to the UNIVERSITY of milestone, earned royalty, patent reimbursement, and Sublicense fees required under
Article 3 applicable to such Sublicensee. If there is more than one Sublicense that survives the termination of this Agreement, the payment obligations for Patent Costs may be prorated among the Sublicensees of relevant Patent Rights. 

2.3 Reservation of Rights. UNIVERSITY reserves the right to: 

(a) use the Invention, Technology and Patent Rights for educational and research purposes; 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 5 













 (b) publish or otherwise disseminate any information about the Invention and Technology at
any time; and 
 (c) allow other nonprofit institutions to use and publish or otherwise disseminate any information about Invention,
Technology and Patent Rights for educational and research purposes. 
 ARTICLE 3. CONSIDERATION 

3.1 Fees and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this
Agreement are partial consideration for the license granted herein to LICENSEE under Technology, and Patent Rights. LICENSEE shall pay UNIVERSITY: 

(a) a license issue fee of fifty thousand dollars (US$50,000), within thirty (30) days after the Effective Date (it being
understood that LICENSEE has fully performed this obligation as of the Execution Date); 
 (b) license maintenance fees of fifteen
thousand dollars (US$15,000) per year and payable on the first anniversary of the Effective Date and annually thereafter on each anniversary; provided however, that LICENSEE’s obligation to pay this fee shall end on the date when LICENSEE is
commercially selling a Licensed Product (it being understood that LICENSEE has fully performed this obligation as of the Execution Date); 

(c) a license restatement fee of [***]; 

(d) milestone payments in the amounts payable according to the following schedule or events: 

 

			
	 Amount
	  	 Date or Event



 

	 	(i)	 For each orphan indication, the following amounts will be paid: 



[***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 6 













 [***] 

For clarity, it is agreed that as of the Execution Date LICENSEE has [***] under such clause with respect to such indication. 

 

	 	(ii)	 For each non-orphan indication, the following amounts will be paid: 



[***] 
 For clarity, it is agreed
that as of the Execution Date LICENSEE [***] under such clause with respect to such indication. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 7 













 (e) during the Royalty Term, an earned royalty of [***]. 

(f) a percentage of all Sublicense Fees received by LICENSEE from its Sublicensees [***]: 

[***]; 
 (g) during the Royalty
Term, on each and every Sublicense royalty payment received by LICENSEE from its Sublicensees on Net Sales of Licensed Product by Sublicensee, the higher of (i) the applicable percentage, determined pursuant to Paragraph 3.1(f), of
royalty amounts received by LICENSEE from such Sublicensee; and (ii) royalties based on the applicable royalty rate in Paragraph 3.1(e) as applied to Net Sales of such Sublicensee. For the sake of clarity, royalties due for Net Sales by
Licensee and/or Affiliate(s), Paragraph 3.1(e) will apply and for Net Sales by Sublicensee, this Paragraph 3.1(g), will apply; 
 (h)
beginning the calendar year of commercial sales of the first Licensed Product by LICENSEE, its Sublicensee, or an Affiliate and if the total earned royalties paid by 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 8 













 LICENSEE under Paragraphs 3.1(e) and (g) to UNIVERSITY in any such year cumulatively amounts to less
than: 
 a. [***] 
 b. [***]

 (“minimum annual royalty”), LICENSEE shall pay to UNIVERSITY on or before February 28 following the last quarter of such year the
difference between the applicable minimum annual royalty above and the total earned royalty paid by LICENSEE for such year under Paragraphs 3.1(e) and (g); provided, however, that for the year of commercial sales of the first Licensed Product, the
amount of minimum annual royalty payable shall be pro-rated for the number of months remaining in that calendar year. 
 3.2 Payment.
All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(h) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1. 

3.3 Patent Costs. LICENSEE shall reimburse UNIVERSITY all past (prior to the Execution Date) and future (on or after the Execution Date)
Patent Costs within [***] following the date an itemized invoice is sent from UNIVERSITY to LICENSEE. In UNIVERSITY’s discretion, for Patent Costs anticipated to exceed [***] (“Anticipated Costs”), UNIVERSITY will inform LICENSEE no
less than [***] prior to the date when Anticipated Costs are incurred. UNIVERSITY may, at its discretion and in accordance with Paragraph 5.1(c), require full advance payment of Anticipated Costs at least [***] before required filing dates
(“Advance Payment Deadline”). [***]. In the event that the Anticipated Costs paid by LICENSEE are greater than the actual cost, the excess amount is creditable against future Patent Costs. In the event that the actual costs exceed the
Anticipated Costs paid in advance by LICENSEE, LICENSEE shall pay such excess costs within [***] following the date an itemized invoice is sent as set forth in Paragraph 4.3. 

3.4 Due Diligence.  

(a) Cystinosis Indication. LICENSEE shall use Commercially Reasonable Efforts to maintain existing regulatory approvals for a Licensed
Product for the Cystinosis Indication and to continue to commercialize a Licensed Product for the Cystinosis Indication in the counties where such regulatory approvals have been obtained. 

(b) HD Indication. LICENSEE shall use Commercially Reasonable Efforts to [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 9 













 [***]. Except as provided in this Paragraph 3.4(b), LICENSEE shall have no other diligence obligations with
respect to the development, commercialization or other exploitation of any Licensed Product for the HD Indication. 
 (c) NASH
Indication. 
 (i) Background. Raptor Pharmaceutical, Inc., executed an agreement with the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, whereby the NIDDK sponsored and conducted the CyNCh study that was designed to evaluate the safety and efficacy of a delayed-release formulation of cysteamine
bitartrate in children with biopsy-confirmed NASH (the “CyNCh Study”). Although the CyNCh Study did not achieve its primary endpoints, following receipt and full analysis of data from the CyNCh Study, LICENSEE will consider whether to
pursue further development of a delayed-release formulation of cysteamine bitartrate for NASH. [***]. 
 (ii) Establishment of NASH
Working Group. The parties shall form a joint working group to further evaluate the possible further development and clinical investigation of a cysteamine bitartrate delayed-release formulation for patients diagnosed with NASH. [***]. 

(iii) Responsibilities of the NASH Working Group. The NASH Working Group shall have the following responsibilities: 

(A) [***]: and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 10 













 (B) within [***] of the first meeting of the NASH Working Group (or such longer period as
agreed by the NASH Working Group), make recommendations (collectively the “NASH Recommendations”) with regard to [***] 
 (iv)
General Provisions Governing NASH Working Group. The following general provisions shall govern the conduct of the NASH Working Group, except as otherwise expressly provided in this Agreement or as agreed by the parties in writing: 

(A) Composition. Each party shall appoint representatives to the NASH Working Group to engage in the NASH evaluation. The NASH Working
Group shall consist of [***] number of representatives from each of the parties, each with the requisite experience and seniority to enable him or her to contribute to evaluation to be conducted by the NASH Working Group. The NASH Working Group
shall include, in the case of UNIVERSITY, [***], and in the case of LICENSEE, its or its parent company’s [***]. Other relevant thought leaders may be included as the parties agree. From time to time, each party may substitute one or more of
its representatives on written notice to the other party. The NASH Working Group shall have co-chairpersons. UNIVERSITY and LICENSEE shall each select from their representatives a co-chairperson for the NASH Working Group, and each party may change
its designated co-chairperson from time to time on written notice to the other party. [***]. 
 (B) Recommendations. The NASH Working
Group shall have the right to adopt such standing rules as shall be necessary or useful for its work to the extent that such rules are not inconsistent with this Agreement. [***]. 

(C) Meetings. The NASH Working Group shall establish a schedule of times for meetings to carry out the work of the NASH Working Group;
provided, that the NASH Working Group shall meet at least [***]. Such meetings may be in person or by telephone, video conference or similar means by which each participant can hear what is said by, and be heard by, the other participants. Subject
to Horizon’s prior approval of any in-person NASH Working group meeting, including the location and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 11 













 
attendees, LICENSEE shall be responsible for [***] of UNIVERSITY representatives incurred for participation in attending such meetings of the NASH Working Group, as arranged by LICENSEE or
otherwise approved in advance by LICENSEE. 
 (D) Agendas and Minutes. The co-chairpersons shall agree in advance of each
meeting on an agenda for such meeting. The co-chairpersons or their designees shall prepare and circulate, for review and approval of the parties, minutes of each meeting within [***] after such meeting. The parties shall agree on the minutes of
each meeting promptly, but in no event later than the next meeting of the NASH Working Group. 
 (v) Determination Regarding Conduct of a
NASH Study. LICENSEE shall consider the NASH Working Group’s final NASH Recommendations and determine whether it will commit to fund and carry out a NASH Study, subject to obtaining any regulatory approvals or authorizations from the FDA
required for the conduct of a NASH Study. [***]. No later than [***] after LICENSEE’s receipt of the NASH Working Group’s final NASH Recommendations or such other date as the parties may agree (the “Determination Date”), LICENSEE
shall notify UNIVERSITY in writing of LICENSEE’s determination. 
 (A) In the event that LICENSEE declines to proceed with a NASH
Study, unless otherwise agreed by the parties, the parties shall cooperate to mutually terminate the NASH Indication pursuant to Paragraph 7.4 within [***] of the Determination Date. 

(B) In the event that LICENSEE elects to proceed with a NASH Study, LICENSEE shall commit to fund up to [***] to plan and conduct, and shall
use Commercially Reasonable Efforts to plan and conduct, a NASH Study, including to commence promptly customary preparatory activities and seek required regulatory approvals or authorizations from the FDA with the goal of achieving first dosing of
an enrolled study subject within [***] of the Determination Date. LICENSEE shall form a steering committee that includes representatives of LICENSEE and one or more thought leaders in relation to NASH, including [***], to consult on the study design
and endpoints and the conduct of the study and shall consider in good faith the recommendations of such advisory group with respect thereto. Notwithstanding the foregoing, unless otherwise agreed by LICENSEE in its sole discretion, in no event shall
LICENSEE’s obligation pursuant to this Paragraph 3.4(c)(v) require LICENSEE (including its Affiliates and Sublicensees) to allocate or incur more than [***] in the aggregate [***] to conduct a NASH Study. 

(vi) In the event that LICENSEE elects to proceed with a NASH Study as allowed by the Regulatory Authority, then pursuant to Sections
3.4(c)(v)(A) and (B) within [***] of the conclusion of such NASH Study, LICENSEE must either: 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 12 













 (x) notify UNIVERSITY in writing that it is declining to further pursue a Licensed Product
for the NASH Indication, in which case the parties shall cooperate to mutually terminate the NASH Indication pursuant to Paragraph 7.4, or 

(y) use Commercially Reasonable Efforts to [***]. 

3.5 No Other Diligence Obligations. The obligations of LICENSEE pursuant to this Paragraph 3.4 represent its only diligence obligations
hereunder, recognizing that LICENSEE may elect to conduct additional activities with respect to one or more Licensed Products in the Field in its discretion to the extent consistent with the its license rights hereunder. 

3.6 Requests for Support for Clinical Investigations. [***]. 

ARTICLE 4. REPORTS, RECORDS AND PAYMENTS 

4.1 Reports and Periodic Meetings.  

(a) Progress Reports and Periodic Meetings.  

(i) Progress Reports. Beginning six (6) months after Effective Date and ending after first commercial sale of the last Licensed
Product to be introduced, LICENSEE shall report to UNIVERSITY progress covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities for the preceding six (6) months to develop and test all Licensed Products and obtain
governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty (60) days of the reporting period and include a summary of work completed, summary of work in progress, current schedule of anticipated
events or milestones, market plans for introduction of Licensed Products, and summary of resources (dollar value) spent in the reporting period. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 13 













 (ii) Periodic Meetings. The parties shall establish a joint team (the
“Project Team”) to meet on a periodic basis and provide a forum for discussing LICENSEE’s progress reports and other matters that relate to LICENSEE’s ongoing development and commercialization activities in relation to
Licensed Products. Each Project Team shall try to meet at least twice each calendar year, or as otherwise agreed by the Project Team. 
 (b)
Royalty Reports. After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on or before each March 31, June 30, September 30 and
December 31 of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter (until the expiration or termination of such period or the earlier expiration
or termination of this Agreement) and shall show: 
 (i) the date of first commercial sale of a Licensed Product in each country; 

(ii) the gross sales, deductions as provided in Paragraph 1.12 and Net Sales during the most recently completed calendar quarter and the
royalties, in US dollars, payable with respect thereto; 
 (iii) the applicable Indication for each type of Licensed Product sold; 

(iv) the number of each type of Licensed Product sold; 

(v) Sublicense Fees and royalties received during the most recently completed calendar quarter in US dollars, payable with respect thereto;

 (vi) the method used to calculate the royalties; and 

(vii) the exchange rates used. 
 If no sales of
Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE shall so report. 

(c) Timely Reports. LICENSEE acknowledges the important value that timely reporting provides in UNIVERSITY’s effective management
of its rights under this Agreement. LICENSEE further acknowledges that failure to render the reports required under this Paragraph 4.1 may harm UNIVERSITY’s ability to manage its rights under this Agreement. As such, reports not submitted by
the required due date under this Paragraph 4.1 will cause to be due by LICENSEE to UNIVERSITY a late reporting fee of [***] per month until such report, compliant with the requirements of this Paragraph 4.1, is received by UNIVERSITY. Payment of
this fee is subject to Paragraph 4.3, Paragraph 7.1 and Paragraph 10.1 herein. 
 4.2 Records & Audits.  

(a) LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products
manufactured, used, and sold, and 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 14 













 
Sublicense Fees received under this Agreement. Such records shall be retained by LICENSEE for at least five (5) years following a given reporting period. 

(b) All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by UNIVERSITY’s Internal Audit
Department or by a Certified Public Accountant selected by UNIVERSITY and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments or other compliance issues. Such inspector shall not disclose to
UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting and underpayment in excess of
[***] for any [***], then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of [***] per year. Such interest shall
be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess of [***] for any [***] period], LICENSEE shall pay the difference within [***]
without interest charge or inspection cost. 
 4.3 Payments.  

(a) General. All fees reimbursements and royalties due UNIVERSITY shall be paid in United States dollars and all checks shall be made
payable to “The Regents of the University of California”, referencing UNIVERSITY’s taxpayer identification number, 95-6006144, and sent to UNIVERSITY according to Paragraph 10.1 (Correspondence). When Licensed Products are sold in
currencies other than United States dollars, LICENSEE shall first determine the earned royalty in the currency of the country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the exchange
rate quoted in the Wall Street Journal on the last business day of the applicable reporting period. 
 (b) Royalty Payments. 

 (i) Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when delivered to a third party or Affiliate. 

(ii) LICENSEE shall pay to UNIVERSITY earned royalties within [***] after the end of each previously stated [***] noted in Paragraph 4.1(b).
Each such payment shall be for earned royalties accrued within such preceding [***]. 
 (iii) Royalties earned on sales occurring or under
Sublicense granted pursuant to this Agreement in any country outside the United States shall not be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country on the payment of royalty income, except that all
payments made by LICENSEE in fulfillment of UNIVERSITY’s tax liability in any particular country may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting from the transfer
of such royalty payments. 
 (iv) If at any time legal restrictions prevent the prompt remittance of part or all royalties by LICENSEE with
respect to any country where a Licensed Product is sold or a 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 15 













 
Sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into US currency and shall pay UNIVERSITY directly from its US sources of fund for as long
as the legal restrictions apply. 
 (v) In the event that any patent or pending patent claim within Patent Rights is held invalid in a final
decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based
solely on that patent or claim or any claim within the Patent Rights that is patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any royalties that accrued before
the date of such final decision, that are based on another patent or claim within the Patent Rights not involved in such final decision, or that are based on the use of Technology. 

(vi) Royalty payments under Article 3, recoveries and settlements under Article 5, and royalty reports under 4.1(b) shall be rendered for any
and all Licensed Products even if due after expiration of the Agreement (in each case with respect to the Net Sales for Licensed Products sold, and settlements entered into and recoveries received (as applicable) during the Term). 

(c) Late Payments. In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay
to UNIVERSITY interest charges at a rate of [***] per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY. 

ARTICLE 5. PATENT MATTERS 

5.1 Patent Prosecution and Maintenance. 

(a) Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to Paragraph 3.3, UNIVERSITY shall diligently prosecute and
maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice. For purposes of clarity, [***]. UNIVERSITY shall provide LICENSEE with copies of all relevant documentation relating to
such prosecution and LICENSEE shall keep this documentation confidential. The counsel shall take instructions only from UNIVERSITY, and all patents and patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY shall in
any event control all patent filings and all patent prosecution decisions and related filings (e.g. responses to office actions) shall be at UNIVERSITY’s final discretion (prosecution includes, but is not limited to, interferences, oppositions
and any other inter partes matters originating in a patent office). 
 (b) UNIVERSITY shall consider amending any patent application in
Patent Rights to include claims reasonably requested by LICENSEE to protect the products contemplated to be sold by LICENSEE under this Agreement. 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 16 













 (c) LICENSEE may elect to terminate its reimbursement obligations with respect to any patent
application or patent in Patent Rights upon [***] written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such application or patent when such notice of termination is received from LICENSEE.
UNIVERSITY, in its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall have no further license with respect thereto. Non-payment of any portion of Patent Costs or
Anticipated Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with respect to such application or patent. UNIVERSITY is not obligated to file, prosecute,
or maintain Patent Rights in any country where LICENSEE is not paying Patent Costs at any time or to file, prosecute, or maintain Patent Rights to which LICENSEE has terminated its license hereunder. 

(d) LICENSEE shall apply for an extension of the term of any patent in Patent Rights if appropriate under the Drug Price Competition and Patent
Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this law. LICENSEE shall prepare all documents for such application, and UNIVERSITY shall execute such documents and take any other additional action as
LICENSEE reasonably requests in connection therewith. 
 5.2 Patent Infringement. 

(a) In the event that UNIVERSITY (to the extent of the actual knowledge of the licensing professional responsible for the administration of
this Agreement) or LICENSEE learns of infringement of potential commercial significance of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with
any evidence of such infringement available to it (the “Infringement Notice”). During the period in which, and in the jurisdiction where, LICENSEE has any exclusive rights under Patent Rights licensed under this Agreement (including with
respect to any indication in the Field), neither party will notify a third party (including the infringer) of infringement or put such third party on written notice of the infringement of any Patent Rights without first obtaining consent of the
other party. 
 (b) Except in the case of any infringement or action covered by Paragraph 5.2(d), LICENSEE shall have the first right, but
not the obligation, to institute suit for patent infringement with respect to any Patent Rights against the infringer, and to institute any defense or counterclaim in connection with any third party infringement claim concerning any Licensed
Product, at LICENSEE’s sole cost and expense, using counsel of its own choice; provided that, except in the case of any infringement or action covered by Paragraph 5.2(d), LICENSEE shall not institute any such suit for patent infringement with
respect to any Patent Rights without the UNIVERSITY’s prior written consent, not to be unreasonably withheld or delayed; provided, further, that LICENSEE shall not institute any such suit for patent infringement unless and until infringing
activity by the infringer has not abated within [***] following the date the Infringement Notice takes effect. UNIVERSITY may voluntarily join (but not control) any such suit at its own expense using counsel of its own choice, but may not thereafter
commence suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit. LICENSEE may not join UNIVERSITY in a suit initiated by LICENSEE without UNIVERSITY’s prior
written consent, with such written consent subject to 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 17 













 
the approval of the UC Board of Regents and a response to the LICENSEE’s request for such consent to be provided as promptly as possible. If, in a suit initiated by LICENSEE, UNIVERSITY is
involuntarily joined other than by LICENSEE, LICENSEE will pay any costs incurred by UNIVERSITY arising out of such suit, including but not limited to, any legal fees of counsel that UNIVERSITY selects and retains to represent it in the suit. In the
event that, in a given country in which a Licensed Product is sold, there is infringing activity of potential commercial significance in such country with respect to Patent Rights in such country that cover the Licensed Product in the Field, which
has not been abated and UNIVERSITY does not agree to join as a party in a suit proposed by LICENSEE to enforce Patent Rights against such infringement in such country, then the parties will meet and discuss a modification to LICENSEE’s
obligation to pay royalties with respect to such Licensed Product in such country under this Agreement. 
 (c) If within a [***] following
the date the Infringement Notice takes effect, infringing activity of potential commercial significance by the infringer has not been abated and if LICENSEE has not brought suit against the infringer and is not otherwise engaged in reasonable
efforts to cause such infringement to be abated, UNIVERSITY may institute suit for patent infringement against the infringer upon [***] prior written notice to LICENSEE; provided that, at the request of LICENSEE, UNIVERSITY will first meet with
LICENSEE and consider in good faith any reasons that LICENSEE believes that such a suit by UNIVERSITY may have an adverse effect. If UNIVERSITY institutes such suit, LICENSEE may not join such suit without UNIVERSITY’s consent and may not
thereafter commence suit against the infringer for the acts of infringement that are the subject of UNIVERSITY’s suit or any judgment rendered in that suit, and UNIVERSITY will control such patent infringement suit, and also will control any
counterclaims and defenses in connection with such suit; provided however that, in the event LICENSEE did not bring suit against the infringer because of UNIVERSITY’s refusal to consent to be joined in a suit brought by LICENSEE, UNIVERSITY
will not bring a suit against the infringer unless it allows LICENSEE, at LICENSEE’s expense, to join and share control of such suit (“UNIVERSITY Refusal Suit”). 

(d) Notwithstanding the foregoing, if either party, for UNIVERSITY, to the extent of the actual knowledge of the licensing professional
responsible for the administration of this Agreement, (i) reasonably believes that a third party may be filing or preparing or seeking to file a generic or abridged drug approval application that refers or relies on regulatory documentation
submitted by LICENSEE to any Regulatory Authority, whether or not such filing may infringe the Patent Rights; (ii) receives any notice of certification regarding the Patent Rights pursuant to the U.S. “Drug Price Competition and Patent
Term Restoration Act” of 1984 (21 United States Code §355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV)) (“ANDA Act”) claiming that any such Patent Rights are invalid or unenforceable or claiming that any such Patent Rights will not be
infringed by the manufacture, use, marketing or sale of a product for which an application under the ANDA Act is filed; or (iii) receives any equivalent or similar certification or notice in any other jurisdiction, it shall (A) notify the
other party in writing identifying the alleged applicant or potential applicant and furnishing the information upon which determination is based and (B) provide with a copy of any such notice of certification within [***] of the date of
receipt. LICENSEE shall have the first, right, but not the obligation, to institute suit with respect to any Patent Rights against any such third party, or its affiliate(s), including any parent entity(ies) or subsidiary(ies), or other entities
working with such third party or its affiliate(s) in connection with such ANDA filing, at LICENSEE’s sole cost and expense, using counsel of its own choice 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 18 













 
and without any requirement of obtaining the consent of UNIVERSITY to the initiation of such suit. Notwithstanding any requirements set forth in Paragraph 5.2(b) with respect to initiation of any
infringement action, LICENSEE shall be permitted to initiate such action at any earlier date in order to ensure compliance with any time limit, if any, set forth in appropriate laws and regulations for filing of such actions; provided, further, that
if LICENSEE fails to confirm in writing to the UNIVERSITY that LICENSEE will bring suit against the third party providing notice of such certification within [***] of receipt of such notice, UNIVERSITY shall have the right, but shall not be
obligated, to bring suit against such third party, in which event UNIVERSITY shall hold LICENSEE harmless from and against any and all costs and expenses of such litigation, including reasonable attorneys’ fees and expenses. To clarify, see
Paragraph 5.4(b) regarding UNIVERSITY being joined in an action brought by LICENSEE. 
 (e) Any monetary recovery or settlement received in
connection with any suit covered by this Paragraph 5.2 will first be shared by UNIVERSITY and LICENSEE equally to cover the litigation costs each incurred, and next shall be paid to UNIVERSITY or LICENSEE to cover any litigation costs it incurred in
excess of the litigation costs of the other. In any suit initiated by LICENSEE under Paragraphs 5.2(b) or (d), any recovery in excess of litigation costs will be shared between LICENSEE and UNIVERSITY as follows: (i) for any recovery other than
amounts paid for willful infringement: (A) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was not a party in the litigation and did not incur any litigation costs; (B) UNIVERSITY will receive [***] of the recovery if
UNIVERSITY was a party in the litigation, but did not incur any litigation costs, including the provisions of Paragraph 5.2(b) above, or (C) UNIVERSITY will receive [***] of the recovery if UNIVERSITY incurred any litigation costs in connection
with the litigation; and (ii) for any recovery for willful infringement, UNIVERSITY will receive [***] of the recovery. In any suit initiated by UNIVERSITY in accordance with the terms of this Agreement, any recovery in excess of litigation
costs will belong to UNIVERSITY, except that in any UNIVERSITY Refusal Suit as defined in Paragraph 5.2(c), any recovery in excess of litigation costs will be shared [***] by UNIVERSITY and [***] by LICENSEE. 

5.3 Invalidity or Unenforceability Defenses or Actions. Each party (in the case of UNIVERSITY to the extent of the actual knowledge of
the licensing professional responsible for the administration of this Agreement or, if applicable, the Patent Manager or Director of Commercialization) shall promptly notify the other party in writing of any alleged or threatened assertion of
invalidity or unenforceability of any of the Patent Rights by a third party of which such party becomes aware. As between the parties, LICENSEE shall have the first right, but not the obligation, to defend and control the defense of the validity and
enforceability of the Patent Rights, at LICENSEE’s sole cost and expense, using counsel of its own choice, when such invalidity or unenforceability is raised as a defense or counterclaim in connection with an infringement action initiated
pursuant to Paragraph 5.2(b) or (d). UNIVERSITY may participate in any such suit or proceeding in the Territory at its own expense using counsel of its own choice; provided that LICENSEE shall retain control of the defense in such suit or
proceeding. If LICENSEE or its designee elects not to defend or control the defense of the Patent Rights in a suit or proceeding brought in the Territory or otherwise fails to initiate and maintain the defense of any such suit or proceeding, then
UNIVERSITY may conduct and control the defense of any such suit or proceeding at its own expense pursuant to Paragraph 5.2(c). For the avoidance of doubt, interferences, oppositions and other inter partes matters originating in a patent office are
subject 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 19 













 
to Paragraphs 5.1(a), (b), (c) and (d); provided that UNIVERSITY and LICENSEE will discuss LICENSEE taking the lead, at LICENSEE’s expense, on inter partes reviews and similar
post-grant matters before the Patent Trial and Appeal Board or similar administrative body that are based on the same subject matter as the claims or counterclaims in an infringement action being led by LICENSEE pursuant to Section 5.2(b) or
(d). 
 5.4 Related Provisions. 

(a) LICENSEE may exercise any rights afforded to it in this Article 5, and satisfy its obligations under this Article 5, directly or by and
through any Affiliate or Sublicensee so designated by LICENSEE for such purpose. Any agreement made by LICENSEE or its designee for purposes of settling litigation or other dispute shall comply with the requirements of Paragraph 2.2 (Sublicenses) of
this Agreement. 
 (b) Each party will cooperate with the other in litigation proceedings instituted or defended hereunder but at the
expense of the party who initiated or is defending the suit (unless such suit is being jointly prosecuted by the parties) including providing reasonable access to relevant documents and other evidence and making its employees available at reasonable
business hours. 
 (c) Any litigation proceedings will be controlled by the party bringing the suit, except that UNIVERSITY may be
represented by counsel of its choice at its cost and expense in any suit brought by LICENSEE. 
 5.5 Patent Marking. LICENSEE shall
mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for all monetary and legal liabilities arising from or caused
by (i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent marking. 
 ARTICLE
6. GOVERNMENTAL MATTERS 
 6.1 Governmental Approval or Registration. If this Agreement or any associated transaction is required
by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United States
or foreign government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process. 

6.2 Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect to the transfer of Licensed
Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations. 

  
 20 













 ARTICLE 7. TERMINATION OR EXPIRATION OF THE AGREEMENT 

7.1 Term and Termination by UNIVERSITY. 

(a) This Agreement shall be deemed to have commenced on the Effective Date and shall continue in effect until the last to expire Royalty Term
anywhere in the Territory unless earlier terminated pursuant to Paragraph 7.1 or 7.2. 
 (b) Subject to Paragraph 7.1(d), if LICENSEE
breaches its material obligations under this Agreement, then UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE. If LICENSEE fails to cure the material breach within ninety (90) days of the Notice of
Default, then (i) in the case of any Notice of Default based on LICENSEE’s material breach of its diligence obligations specified in Paragraphs 3.4(a), (b) or (c) with respect to a Cystinosis Indication, NASH Indication or HD
Indication, as applicable, UNIVERSITY shall have the right and option, solely with respect to the applicable indication, to either terminate the license granted herein to such indication (in which case, the Field will exclude that terminated
indication) or convert LICENSEE’s exclusive license to such indication to a nonexclusive license, and (ii) in the case of any other such material breach, UNIVERSITY may terminate this Agreement and the license granted herein. UNIVERSITY
may exercise any such right to terminate or convert the license (in the case of clause (i), solely with respect to the applicable indication) by providing to LICENSEE a second written notice (in the case of a termination, a “Notice of
Termination” and in the case of a license conversion, a “Notice of License Conversion”) to LICENSEE. If either such notice is sent to LICENSEE, this Agreement (or in the case of clause (i), the license solely with respect to the
applicable indication) shall automatically terminate or the license shall convert to a non-exclusive license with respect to the subject indication, as applicable, on the effective date of that notice. Termination of this Agreement in its entirety
or termination of the license granted herein with respect to any indication shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY. During the term of any
such Notice of Default or period to cure, to the extent the default at issue is a failure to pay past or ongoing Patent Costs as provided for under this Agreement as provided in Paragraph 3.3, UNIVERSITY shall have no obligation to incur any new
Patent Costs under this Agreement and shall have no obligation to further prosecute Patent Rights or file any new patents under Patent Rights. 

(c) This Agreement will terminate immediately, without the obligation to provide ninety (90) days’ notice as set forth in Paragraph
7.1(b), if LICENSEE files a claim including in any way the assertion that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at
the written urging of the LICENSEE. 
 7.2 Termination by LICENSEE.  

(a) LICENSEE shall have the right at any time and for any reason, upon a ninety (90) day written notice to UNIVERSITY, either to terminate
this Agreement in its entirety or to terminate the licensed granted herein with respect to any one or more indication(s) (in which case, the Field will exclude that terminated indication(s)). Said notice shall state LICENSEE’s reason for
terminating this Agreement. 

  
 21 













 (b) Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or
liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising
under this Agreement prior to termination. 
 7.3 Survival on Termination or Expiration. The following Paragraphs and Articles shall
survive the termination or expiration of this Agreement: 
 (a) Paragraph 2.2(c); 

(b) Article 4 (Reports, Records and Payments); 

(c) Paragraph 7.3 (Survival on Termination or Expiration); 

(d) Paragraph 7.5 (Disposition of Licensed Products on Hand); 

(e) Article 8 (Limited Warranty and Indemnification); 

(f) Article 9 (Use Of Names and Trademarks); 

(g) Paragraph 10.2 hereof (Secrecy); 

(h) Paragraph 10.5 (Failure to Perform); and 

(i) Paragraph 10.6 (Governing Law). 

7.4 Termination of License Solely to a Specific Indication. If the license granted in this Agreement is terminated solely with respect
to a given indication under the provisions of Paragraph 3.4(c)(v)(A) or Paragraph 3.4(c)(vi) with respect to the NASH Indication or under the provisions of Paragraph 7.1(b) or Paragraph 7.2(a) with respect to any specific
indication, but this Agreement is not terminated in its entirety, then following such termination solely with respect to a given indication, the provisions of this Agreement identified in Paragraph 7.3 shall remain in effect with respect to the
terminated indication, as applicable (to the extent they would survive and apply in the event the Agreement expires or is terminated in its entirety) and all provisions not surviving in accordance with the foregoing shall terminate with respect to
the terminated indication upon the effective date of termination thereof. This Agreement shall continue in effect in accordance with its terms with regard to all indications other than any such terminated indication. If UNIVERSITY grants a license
under the Patent Rights or Technology for such terminated indication to any third party, UNIVERSITY shall use reasonable efforts to cause such third party, on behalf of itself and its affiliates, to agree not to make, have made, sell, have sold,
offer for sale or import (including for clinical or commercial purposes) any Licensed Product in the Field and such agreement shall provide that LICENSEE is a third party beneficiary with respect to such covenant, which shall be enforceable by
LICENSEE. 
 7.5 Disposition of Licensed Products on Hand. Upon termination of this Agreement in its entirety or with respect to a
particular indication, LICENSEE may dispose of all previously made or partially made Licensed Product within a period of [***] of 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 22 













 
the effective date of such termination provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement, including but
not limited to the rendering of reports and payment of royalties required under this Agreement. 
 7.6 Availability of LICENSEE data and
rights. In the event that the license granted in this Agreement is terminated with respect to the NASH Indication or the HD Indication and subject to Section 2.2(c), in the event that the UNIVERSITY grants or reasonably expects to grant a
license under the Patent Rights to a third party to develop or commercialize a Licensed Product for such terminated indication, following UNIVERSITY’s reasonable request, UNIVERSITY and LICENSEE shall discuss in good faith whether LICENSEE
would be willing grant any license or other rights to such third party with respect to clinical data or patent rights owned by LICENSEE that would be reasonably necessary or useful for the further development and commercialization of a Licensed
Product for the such terminated indication, it being understood and agreed that the grant of such license or other rights is within the sole discretion of LICENSEE and would only be considered on commercially reasonable terms. 

ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION 

8.1 Limited Warranty.  

(a) UNIVERSITY warrants as of the Effective Date and the Execution Date that it has the lawful right to grant this license. This warranty does
not include Patent Rights to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventors to third parties prior to the Effective Date. 

(b) The license granted herein and the associated Technology are provided “AS IS” and without WARRANTY OF MERCHANTABILITY or WARRANTY
OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights or Technology will not infringe any other patent or
other proprietary rights. 
 (c) EXCEPT WITH RESPECT TO A BREACH OF PARAGRAPH 8.1(a) ABOVE, A BREACH OF CONFIDENTIALITY UNDER
PARAGRAPH 10.2 OR, IN THE CASE OF LICENSEE, LICENSEE’S DUTIES FOR CLAIMS OF THIRD PARTIES UNDER PARAGRAPH 8.2, NEITHER PARTY WILL BE LIABLE FOR ANY LOST PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED
DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT
FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

(d) Nothing in this Agreement shall be construed as: 

  
 23 













 (i) a warranty or representation by UNIVERSITY as to the validity or scope of any Patent
Rights; 
 (ii) a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this
Agreement is or shall be free from infringement of patents of third parties; 
 (iii) an obligation to bring or prosecute actions or suits
against third parties for patent infringement except as provided in Paragraph 5.2 hereof; 
 (iv) conferring by implication, estoppel or
otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or 

(v) an obligation to furnish any know-how not provided in Patent Rights and Technology; or 

(vi) an obligation to update Technology. 

8.2 Indemnification.  

(a) LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend UNIVERSITY and its officers, employees, and agents;
the sponsors of the research that led to the Invention; and the inventors of patents or patent applications under Patent Rights, and their employers; against any and all claims, suits, losses, damages, costs, fees, and expenses resulting from, or
arising out of, the exercise of this license or any Sublicense, except to the extent arising out of or related to Patent Rights to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventors to third parties. This indemnification will
include, but will not be limited to, any product liability. 
 (b) From and after the Execution Date, LICENSEE, at its sole cost and expense,
shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self-insurance as follows: 

(i) comprehensive or commercial general liability insurance (contractual liability included) with limits of at least: (A) each
occurrence, five million dollars (US$5,000,000); (B) products/completed operations aggregate, ten million dollars (US$10,000,000); (C) personal and advertising injury, five million dollars (US$5,000,000); and (D) general aggregate
(commercial form only), ten million dollars (US$10,000,000); Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE is doing business; 

(ii) the coverage and limits referred to above shall not in any way limit the liability of LICENSEE; and 

(iii) If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of
this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date. 

  
 24 













 (c) Upon request, LICENSEE shall furnish UNIVERSITY with certificates of insurance showing
compliance with all requirements. Such certificates shall: (i) indicate that UNIVERSITY has been endorsed as an additional insured party under the coverage referred to above; and (ii) include a provision that the coverage shall be primary
and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by UNIVERSITY. LICENSEE shall provide [***] advance written notice to the UNIVERSITY of any policy
modification with respect to the matters addressed in clause (i) or (ii) of this Paragraph 8.2(c). 
 (d) UNIVERSITY shall notify
LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this
Article. 
 ARTICLE 9. USE OF NAMES AND TRADEMARKS 

9.1 Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade
name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by LICENSEE of the name, “The Regents of the University of
California” or the name of any campus of the University Of California is prohibited, without the express written consent of UNIVERSITY. 

9.2 UNIVERSITY may disclose to the Inventors the terms and conditions of this Agreement upon their request. If such disclosure is made,
UNIVERSITY shall request the Inventors not disclose such terms and conditions to others. 
 9.3 UNIVERSITY may acknowledge the existence of
this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California
Public Records Act. LICENSEE hereby grants permission for UNIVERSITY (including UCSD) to include LICENSEE’s name and a link to LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s (including
UCSD’s) websites that showcase technology transfer-related stories. 
 ARTICLE 10. MISCELLANEOUS PROVISIONS 

10.1 Correspondence. Any notice or payment required to be given to either party under this Agreement shall be deemed to have been
properly given and effective: 
 (a) on the date of delivery if delivered in person, or 

(b) five (5) days after mailing if mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to
such other address as is designated by written notice given to the other party. 
 If sent to LICENSEE: 

Horizon Orphan LLC 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 25 













 150 South Saunders Road 

Lake Forest, Illinois 60045 

Attention: General Counsel 

Phone: +1 224-393-3233 (direct) 

Fax: +1-847-572-1631 

Attention: 
 If
sent to UNIVERSITY by mail: 
 University of California, San Diego 

Office of Innovation and Commercialization 

9500 Gilman Drive 

Mail Code 0910 

La Jolla, CA 92093-0910 

Attention: Director of Commercialization 

If sent to UNIVERSITY by courier: 

University of California, San Diego 

Office of Innovation and Commercialization 

10300 North Torrey Pines Road 

Torrey Pines Center North, Third Floor La Jolla, CA 92037 

Attention: Director of Commercialization 

10.2 Secrecy.  
 (a)
“Confidential Information” shall mean (i) with respect to UNIVERSITY, information, including Technology, relating to the Invention and disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, and (ii) with respect
to LICENSEE, information disclosed by LICENSEE or any of its Affiliates to UNIVERSITY, or its employees or agents (including Drs. Dohil or Barshop) on or after the Execution Date that relates to (i) the business or operations of LICENSEE or any
of its Affiliates, (ii) this Agreement or any activities of LICENSEE in relation to any Licensed Product, including any such information disclosed by or on behalf of LICENSEE in in connection with the NASH Working Group or the Project Team, or
(iii) actual or planned patent prosecution or enforcement activities of LICENSEE or any of its Affiliates. The disclosing party will endeavor to mark Confidential Information (or cause such information to be marked) as “confidential”
and reduce orally disclosed Confidential Information to writing within thirty (30) days of disclosure, provided that if any Confidential Information is disclosed and not so marked or reduced to writing, the receiving party agrees to treat such
Confidential Information (or cause such information to be treated) as confidential to the extent that a reasonable person would consider such Confidential Information as confidential given the content and the circumstance of the disclosure. 

(b) Each party and its employees and agents shall: 

(i) use the Confidential Information for the sole purpose of performing under the terms of this Agreement; 

  
 26 













 (ii) safeguard Confidential Information against disclosure to others with the same degree
of care as it exercises with its own data of a similar nature; 
 (iii) not disclose Confidential Information to others (except to its
employees and agents, or, in the case of LICENSEE as the receiving party, to its consultants or actual or proposed Sublicensees or acquirers who are bound to LICENSEE by a like obligation of confidentiality) without the express written permission of
UNIVERSITY, except that receiving party shall not be prevented from using or disclosing any of the Confidential Information that: 
 (A) the
receiving party can demonstrate by written records was previously known to it; 
 (B) is now, or becomes in the future, public knowledge
other than through acts or omissions of the receiving party or its employees or agents; 
 (C) is lawfully obtained by the receiving party
from sources independent of the disclosing party; or 
 (D) is required to be disclosed by law or a court of competent jurisdiction; 

(E) is disclosed by the receiving party or its designee in connection with filings or submissions to Regulatory Authorities with respect to
Licensed Products as permitted under the terms of this Agreement; and 
 (c) The secrecy obligations provided in this Paragraph 10.2 with
respect to Confidential Information of the disclosing party shall continue for a period ending [*...***...] from the expiration or termination date of this Agreement. 

10.3 Assignability. This Agreement is binding upon and inures to the benefit of UNIVERSITY, its successors and assigns. But it is
personal to LICENSEE and assignable by LICENSEE only with the written consent of UNIVERSITY. Notwithstanding the foregoing, the consent of UNIVERSITY will not be required if the assignment is in conjunction with the transfer of all or substantially
all of the business of LICENSEE to which this Agreement relates or is to an Affiliate of LICENSEE. 
 10.4 No Waiver. No waiver by
either party of any breach or default of any covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default. 

10.5 Failure to Perform. In the event of a failure of performance due under this Agreement and if it becomes necessary for either party
to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorney’s fees in addition to costs and necessary disbursements. 

10.6 Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but


  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 27 













 
the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application. 

10.7 Force Majeure. A party to this Agreement may be excused from any performance required herein if such performance is rendered
impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other
serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall resume. 

10.8 Headings. The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of
or to affect the meaning or interpretation of this Agreement. 
 10.9 Entire Agreement. This Agreement embodies the entire
understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof, including the Prior Agreement. 

10.10 Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and
signed on behalf of each party. 
 10.11 Severability. In the event that any of the provisions contained in this Agreement is held to
be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or unenforceable
provisions had never been contained in it. 

  
 28 













 IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in
duplicate originals, by their respective and duly authorized officers on the day and year written. 
  

									
	HORIZON ORPHAN LLC:	 		 	THE REGENTS OF THE
		 		 		 	UNIVERSITY OF CALIFORNIA:
					
	By:	 	 /s/ Brian K. Beeler
	 		 	By:	 	 /s/ Ruben Flores

	Name:	 	Brian K. Beeler	 		 	Name:	 	Ruben Flores
	Title:	 	Executive Vice President	 		 	Title:	 	Director, Office of Innovation
		 	General Counsel	 		 		 	and Commercialization
				
	Date: 5/19/17	 		 		 	Date: 5/31/17


  
 29 














			
	THE REGENTS OF THE
	UNIVERSITY OF CALIFORNIA:
		
	By:	 	 /s/ Lisa Meredith

	Name:	 	Lisa Meredith
	Title:	 	Associate Director,
		 	Office of Contract and
		 	Grant Administration
	
	Date: May 31, 2017


  
 30 













 EXHIBIT A 

Patent Rights 
  

																	
	 Title
	  	Territory	  	Date of Filing	  	Application No.	  	Publication No.	  	Patent No.	  	Status	  	Comment	  	Owner

 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-1 













 [***] 
  

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-2 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-3 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-4 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-5 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-6 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-7 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-8 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-9 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-10 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-11 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-12 













 [***] 

  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-13 













 [***] 
  

	(1)	 [***]. 


  

	(2)	 [***]. 



  
 [***] = CERTAIN
CONFIDENTIAL INFORMATION OMITTED 
 A-14